4G Clinical is one of Fast Company’s Best Workplaces for Innovators

{ object.primary_image.title }}

The clinical trials company checks in at number eight on the list of 100. Small and nimble, clinical trials company 4G Clinical moves quickly to leverage technology to expedite medication for FDA approval. When the coronavirus hit, the team pivoted to focus on delivering drugs to step up clinical trials. “Starting in mid-March, we have been at the forefront of getting trials directly to people’s homes,” says founder and CEO David Kelleher. “When COVID-­19 hit, we acted fast.” Read Full Story

Read Full Article on Fast Company

AbCellera wins Fast Company’s Innovative Team of the Year award

{ object.primary_image.title }}

AbCellera’s Pandemic Prevention Platform team brought the first COVID-19 antibody to clinical trials in under 90 days. Together with Eli Lilly and NIAID’s Vaccine Research Center, AbCellera’s Pandemic Prevention Platform team combined microfluidics, data science, machine learning, bioinformatics, and genomics to bring the first COVID-19 antibody to clinical trials in under 90 days, a process that typically requires three to six years. In June Eli Lilly began two Phase 1 clinical trials of COVID-19 antibodies isolated by AbCellera. “People have pushed themselves to the very limits of their endurance in this race against the virus,” says AbCellera head of R&D Ester Falconer. Read Full Story

More

This company is preparing to manufacture 100 million doses of COVID-19 vaccines

{ object.primary_image.title }}

The pharmaceutical company Sanofi is retrofitting current manufacturing facilities so they’ll be able to pump out millions of COVID-19 vaccine doses when it is finally developed. There are 76 vaccine candidates for COVID-19, five of which are in clinical trials. It will take at least 18 months to determine if these vaccines are effective and safe enough to distribute en masse. Then, distributing them to millions of people will require an incredible feat of manufacturing. Read Full Story

More

How TB Alliance’s Mel Spigelman created a promising new anti-tuberculosis drug

{ object.primary_image.title }}

For demonstrating how a nonprofit can develop drugs as well as Big Pharma can, Mel Spigelman is one of Fast Company’s Most Creative People in Business for 2020 In August 2019, TB Alliance’s pretomanid became one of three new anti-tuberculosis drugs approved by the FDA, and the first developed and registered by a nonprofit. When internist Mel Spigelman joined the organization (a product-development partnership, or PDP) as its head of R&D, in 2003, drug-resistant TB was an emerging public health priority, with an estimated 300,000 new cases per year worldwide. TB Alliance had recently licensed rights to develop a promising new drug from the biotech company Chiron. Spigelman jump-started its development, hiring a team with “expertise from early discovery through registration,” he says. “I wanted to be on a basis of equals with drug-development partners” such as Mylan and GlaxoSmithKline, which would enable the organization to move projects forward more …

More

Boston Scientific is one of Fast Company’s Best Workplaces for Innovators

{ object.primary_image.title }}

Last year, Boston Scientific launched 87 new products. In 2019, the medical device company launched 87 new products, including a revolutionary single-use duodenoscope developed by a 150-person team of internal engineers and clinical experts. According to the FDA, more than 5% of reusable scopes are contaminated with pathogens that can cause fatal infections. “The team was huge,” says executive vice president Dave Pierce, “and the investment significant. We were lucky to have the resources to put against this. You can’t do it on a shoestring.” Read Full Story

More

Healthcare will never be the same: 8 experts on the future of medicine around the globe

{ object.primary_image.title }}

The leaders of the Mayo Clinic, Cleveland Clinic, Doctors Without Borders, and more tell us how healthcare is being transformed by the COVID-19 pandemic. For Fast Company’s Shape of Tomorrow series , we’re asking business leaders to share their inside perspective on how the COVID-19 era is transforming their industries. Here’s what’s been lost—and what could be gained—in the new world order. Read Full Story

More

I’m a tech CEO. Here’s why I’m not taking a salary during COVID-19

{ object.primary_image.title }}

As the founder and CEO of the fintech company Gravity Payments, I’ve decided to prioritize my employees’ and clients’ well-being over my own compensation during the coronavirus crisis. In early March, as the coronavirus arrived in the United States and businesses began shutting down, our company started losing money fast. We’re a credit card processor that works primarily with small and midsize businesses such as restaurants, retails shops, and independent clinics, which means our revenue is directly tied to theirs. By the end of the month, we were down 55% from expectations and losing $30,000 a day. Read Full Story

More

Subscribe to our newsletter

Join our newsletter and never miss out trending marketing news.

HitcountVariables(pk=6409, ajax_url='/api/hit/ajax/', hits='9')